Singapore: Biovest International has decided to spin off its instrument and contract manufacturing offerings into a single wholly-owned subsidiary named Cell Culture Company.

Cell Culture Company will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic, and animal healthcare industries.

Since the late 1990s, Biovest's primary focus has been the commercialization of personalized immunotherapies. That work will continue under the Biovest name. "The spin-off of Cell Culture Company will ensure that our instrument and CMO customers will be better served through increased focus and investment," said Christiaan Engstrom, president, Cell Culture Company President.